Literature DB >> 27250046

Seven-year Observational Study on the Association between Glycemic Control and the New Onset of Macroangiopathy in Japanese Subjects with Type 2 Diabetes.

Tomohiko Kimura1, Hideaki Kaneto, Yukiko Kanda-Kimura, Masashi Shimoda, Shinji Kamei, Takatoshi Anno, Fumiko Kawasaki, Mitsuru Hashiramoto, Michihiro Matsuki, Tomoatsu Mune, Kohei Kaku.   

Abstract

Objective To examine the association between glycemic control and the new onset of macroangiopathy in Japanese subjects with type 2 diabetes. Methods We examined seven-year follow-up data for 572 patients. We divided the subjects by the average of seven-year glycemic control based on the guidelines. First, we excluded the subjects with a past history of macroangiopathy and then examined the incidence of the new onset of macroangiopathy. Results The incidence of ischemic heart disease (IHD) was 1.0% per year, and that of cerebral vascular disease (CVD) was 1.0% per year. However, IHD events were not observed at all for five years in the most intensive glycemic control group (HbA1c<6%). Similarly, CVD events were not observed at all for seven years in the most intensive glycemic control group (HbA1c<6%). In addition, the cumulative incidence rate of IHD tended to increase as the glycemic control became poorer (HbA1c<6%, 4.5%; 6%≤HbA1c<7%, 6.0%; 7%≤HbA1c<8%, 7.2%; HbA1c≥8%, 10.7%). Furthermore, a logistic regression analysis showed that the duration of diabetes and HbA1c level were independent risk factors contributing to the onset of IHD, but not to the onset of CVD. Conclusion This seven-year observational study showed the possible association between glycemic control and the onset of macroangiopathy in a total of 572 Japanese subjects with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27250046     DOI: 10.2169/internalmedicine.55.4952

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus.

Authors:  Yuichiro Iwamoto; Tomohiko Kimura; Fuminori Tatsumi; Toshitomo Sugisaki; Masato Kubo; Erina Nakao; Kazunori Dan; Ryo Wamata; Hideyuki Iwamoto; Kaio Takahashi; Junpei Sanada; Yoshiro Fushimi; Yukino Katakura; Masashi Shimoda; Shuhei Nakanishi; Tomoatsu Mune; Kohei Kaku; Hideaki Kaneto
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

2.  Verification of Kumamoto Declaration 2013 and Glycemic Targets for Elderly Patients with Diabetes in Japan for prevention of diabetic complications: A retrospective longitudinal study using outpatient clinical data.

Authors:  Shuhei Nakanishi; Hidenori Hirukawa; Masashi Shimoda; Fuminori Tatsumi; Kenji Kohara; Atsushi Obata; Tomohiko Kimura; Seizo Okauchi; Tomoe Kinoshita; Junpei Sanada; Yoshiro Fushimi; Momoyo Nishioka; Akiko Mizoguchi; Tomoatsu Mune; Kohei Kaku; Hideaki Kaneto
Journal:  J Diabetes Investig       Date:  2018-09-10       Impact factor: 4.232

3.  Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.

Authors:  Junpei Sanada; Tomohiko Kimura; Masashi Shimoda; Akiko Tomita; Yoshiro Fushimi; Tomoe Kinoshita; Atsushi Obata; Seizo Okauchi; Hidenori Hirukawa; Kenji Kohara; Fuminori Tatsumi; Shuhei Nakanishi; Tomoatsu Mune; Kohei Kaku; Hideaki Kaneto
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-06       Impact factor: 5.555

4.  Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis.

Authors:  John Peter Mitsios; Elif Ilhan Ekinci; Gregory Peter Mitsios; Leonid Churilov; Vincent Thijs
Journal:  J Am Heart Assoc       Date:  2018-05-17       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.